|
CDC23 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.56729999773498E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.36279999957334E-07 |
| Normal-vs-Stage2 |
4.026100E-02 |
| Normal-vs-Stage3 |
7.51559999789819E-08 |
| Normal-vs-Stage4 |
5.10609998727318E-10 |
| Stage1-vs-Stage2 |
1.675400E-01 |
| Stage1-vs-Stage3 |
1.598570E-01 |
| Stage1-vs-Stage4 |
8.443400E-03 |
| Stage2-vs-Stage3 |
4.246100E-02 |
| Stage2-vs-Stage4 |
6.141300E-03 |
| Stage3-vs-Stage4 |
2.540200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.1497999996557E-08 |
| Normal-vs-AfricanAmerican |
9.116000E-03 |
| Normal-vs-Asian |
3.57419999996722E-06 |
| Caucasian-vs-AfricanAmerican |
2.727200E-01 |
| Caucasian-vs-Asian |
8.483800E-01 |
| AfricanAmerican-vs-Asian |
3.793600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.13769999998681E-06 |
| Normal-vs-Female |
1.24459999972792E-07 |
| Male-vs-Female |
6.362800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.71140000019221E-07 |
| Normal-vs-Age(41-60Yrs) |
1.59309999969715E-07 |
| Normal-vs-Age(61-80Yrs) |
1.23149999975425E-07 |
| Normal-vs-Age(81-100Yrs) |
1.151610E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.633600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.355200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.321400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.581600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.222600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.479600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.440500E-03 |
| Classical-VS-Follicular |
2.774800E-01 |
| Classical-VS-Other |
2.875400E-01 |
| Classical-VS-Normal |
1.00410000003492E-06 |
| Tall-VS-Follicular |
3.317100E-03 |
| Tall-VS-Other |
9.765000E-01 |
| Tall-VS-Normal |
5.46849999727428E-08 |
| Follicular-VS-Other |
1.807820E-01 |
| Follicular-VS-Normal |
9.580200E-04 |
| Other-VS-Normal |
2.300300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.7635999994865E-07 |
| Normal-vs-N1 |
7.72619968003596E-10 |
| N0-vs-N1 |
1.239810E-02 |
|
|
